Trastuzumab biosimilar (Celltrion)

曲妥珠单抗生物类似药（Celltrion）

Report date: 2026/04/24 20:01:59

Base Information

Drug NameTrastuzumab biosimilar (Celltrion)

Drug Alias NameTrastuzumab-PKRB曲妥珠单抗生物仿制药（Celltrion）HerzumaCT-P6CT-P06

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsMetastatic breast cancerStomach NeoplasmsBreast Neoplasms

Global Approved IndicationsStomach NeoplasmsBreast Neoplasms

Approved Indications in ChinaN/A

Original Approved Country/TerritorySouth Korea

Original Approved Date2014/01/01

Country/TerritoryUnited StatesSouth KoreaEU +[4]

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesCelltrion Inc

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsStomach NeoplasmsBreast Neoplasms

Inactive IndicationsMetastatic breast cancer

ATC CodeL01XC03